The Science Journal of the Lander
College of Arts and Sciences
Volume 13
Number 1 Fall 2019
2019

Endorphins, Endocannabinoids and Runners’ High
Elisheva Winiarz
Touro College

Follow this and additional works at: https://touroscholar.touro.edu/sjlcas
Part of the Biology Commons, and the Pharmacology, Toxicology and Environmental Health
Commons

Recommended Citation
Winiarz, E. (2019). Endorphins, Endocannabinoids and Runners’ High. The Science Journal of the Lander
College of Arts and Sciences, 13(1). Retrieved from https://touroscholar.touro.edu/sjlcas/vol13/iss1/4

This Article is brought to you for free and open access by the Lander College of Arts and Sciences at Touro Scholar.
It has been accepted for inclusion in The Science Journal of the Lander College of Arts and Sciences by an
authorized editor of Touro Scholar. For more information, please contact touro.scholar@touro.edu.

-

Endorphins, Endocannabinoids and Runners’ High
Elisheva Winiarz
Elisheva Winiarz graduated with a B.S. degree in Biology in June 2019 and will be attending Touro’s Doctor of
Physical Therapy Program, in Manhattan.

Abstract
Modern science takes at face value the fact that exercise is beneficial for man’s health. In recent years, medical health professionals have begun to harness exercise as a treatment for a broader range of maladies. Since various studies found increased exercise
to correlate with higher levels of endorphins, most believed that the endorphins were directly responsible for what the vernacular
dubbed “Runner’s High.” Scientists have sought to either augment or wholly disprove the endorphin hypothesis with further
studies. Major Depressive Disorder, or MDD, is an affective condition affecting a significant portion of the general population.
Aerobic exercise is increasingly being revealed to be an encouraging treatment for all types of depression and anxiety. The HPA
Axis allows one to comfortably exercise without experiencing the extremely stressful symptoms that characterize psychological
stress, such as depression, anxiety, fear, etc. Runners’ High is the “…happiness, elation…inner harmony, boundless energy, and…
reduction in pain sensation” that ensues following prolonged aerobic activity. Endorphins are the body’s naturally occurring opiates.
The Neurogenesis Hypothesis states that “a decrease in the synthesis of new neurons in the adult hippocampus might be linked
to major depressive disorder.” Further research implicates BDNF (Brain-Derived Neurotrophin Factor) in exercise-induced neurogenesis. The thought was that beta endorphins are what stimulate increased neurogenesis, in turn causing a decrease in MDD.
β-endorphins are large molecules that are too bulky to pass through the BBB and therefore cannot be the cause any changes to
occur within the brain. Researchers and scientists have thus turned their attention to endogenous endocannabinoids as the true
source of analgesia, sedation, anxiolysis and reduced depression found in endurance exercisers. Chief ligand anandamide (AEA)
engenders elevated levels of BDNF (Brain Derived Neurotrophic Factor) during exercise and return-to-baseline levels post-exercise. Endocannabinoids modulate nociception by affecting the Periaqueductal Gray system (PAG). Endogenous cannabinoids and
exogenous cannabinoids (marijuana) act in similar fashions, leading to the addictive qualities of exercise. Compelling evidence has
ascertained that endogenous endocannabinoids are the underlying cause of the many positive effects of aerobic activity.
Introduction
Modern science takes as face value the fact that exercise is
beneficial for man’s health. Hippocrates was known to say,
“Even when all is known, the care of a man is not yet complete,
because eating alone will not keep a man well; he must also
take exercise...” While to a contemporary society this concept
seems rather primitive and simplistic, it is a truth that forms
the basis of modern health sciences. However, it has only been
in recent years that medical health professionals have begun to
harness exercise as a treatment for a broader range of maladies.
Exercise is widely known to help keep one’s weight down, tone
muscles and enhance physical fitness. Scientists are perpetually
expanding their knowledge of exercise and what kind of effects
it has on the brain and the body’s systems. An understanding
of the neuronal activity, neurotransmitter actions and chemical
releases that are the responses to varying degrees of exercise
can be applied to treat disease and improve lives. One such
application is exercise as a treatment for Major Depressive
Disorder (MDD). MDD had previously been treated solely with
antidepressants, but more recently is being dealt with using a
combination of medication and exercise. Various case studies
have undertaken to prove the relationship between exercise
and positive changes in the MDD brain. Once the neuronal and
chemical effects of exercise were established, it naturally led
to the conclusion that depressive symptoms lessened due to a
proliferation of certain positive hormones that were released
into the brain in response to exercise. With further investigations, the popular conclusion was that the feel-good high associated with exercise is caused by endorphins, opioid hormones
that appear to increase in response to exercise. Since various
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studies found increased exercise to correlate with higher levels
of endorphins, most believed that the endorphins were directly
responsible for what the vernacular dubbed “Runner’s High.”
Since then, scientists have sought to either augment or wholly
disprove the endorphin hypothesis with further studies.

Methods
The search engines used include ProQuest, EbscoHost, and
GoogleScholar. Tributary information was also obtained using
Wikipedia, the New York Times and WebMD.

Discussion
Major Depressive Disorder, or MDD, is an affective condition
affecting a significant portion of the general population. In
America today, about 5% of all people will eventually be diagnosed with MDD. Quality of life with MDD is radically impaired,
and basic life functions such as eating, sleeping and maintaining
personal hygiene can be affected. It has been found that roughly 10% of people diagnosed with MDD will probably commit
suicide. This is all due to the overwhelming, pervasive feelings of severe depression that characterize Major Depressive
Disorder. Deficits in executive function are also consequences
of MDD. Patients tested with a Stroop Task, Go/No Go Task,
Task-Switching Paradigm and Flanker Tasks all scored low in
reaction times, indicating deficits in executive function ability
(Ernst, et al. 2006). Previously, MDD had been treated solely
with antidepressant medications such as SSRIs (selective serotonin reuptake inhibitors). The anti-depressant medication field
is an ever-growing industry, despite limited success and many
unwarranted side effects. For examples, anti-depressants stop
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working after a while, since the body and brain become accustomed to the drug and gain a tolerance for it. In such a case,
the dose would have to continuously be raised in order to have
any effect. Furthermore, if one abruptly stops taking the dosage
of medication, withdrawal symptoms such as “dizziness, loss of
coordination, fatigue, tingling, burning, blurred vision, insomnia,
and vivid dreams” may incur. Additionally, the patient may experience “nausea or diarrhea, flu-like symptoms, irritability, anxiety,
and crying spells.” This tendency is called the “Discontinuation
syndrome” and is obviously best to be avoided. Other negative side effects might include insomnia, diarrhea and stomach
aches, headaches, joint and muscle pain, reduced blood clotting
capacity due to lowered concentration of serotonin in platelets and possible increased tendency towards violence and/or
self-destructive behaviors. A Black Box warning was even issued
in 2004 by the FDA against SSRIs, warning of the possible risk of
“suicidal thoughts, hostility, and agitation in children, teens and
young adults” (Harvard, 2019).
Between 30-35% of patients on medication do not even respond to the antidepressant treatment at all. The unpleasant
side effects considerably compromise the patients’ quality of
life in many areas and make the medications undesirable as a
primary treatment for depression. Furthermore, there is a high
relapse rate found in patients treated with antidepressants, leading to a need for alternative and/or supplementary treatments
(Blumenthal, et al. 1999).
Aerobic exercise is increasingly being revealed to be an encouraging treatment for all types of depression and anxiety
(Heijnen, et al. 2016). A study was performed testing MDD
symptoms in response to exercise. Participants were accepted
for the study if they displayed depressive criteria as expressed
in the DSM-IV and other symptoms such as “sleep disturbance,
weight loss…psychomotor retardation or agitation, feelings of
worthlessness or excessive guilt, impaired cognition…and recurrent thoughts of death.” They also had to receive a score of
at leave 13 on the HAM-D test. The HAM-D is a clinical rating
scale used to measure levels of depression. Scores of thirteen
to eighteen is mildly depressed, above 18 is severely depressed.
Each of the subjects of the study were assigned to one of three
groups – exercise treatment, medication treatment, and a combination of exercise and medication treatment. The assignment
of groups was a randomized procedure to ensure that equally
depressed participants were assigned across the groups. The
exercise group met three times a week for 16 weeks, engaging
in personalized exercise protocol according to their individual
heart rate capability. The classes were overseen by a “trained
exercise physiologist.” The medication group was administered
the SSRI sertraline, specifically used due to its “documented
efficacy and favorable side effect profile.” Dosages were administered by the staff psychiatrist at intermittent weeks. The combination group concurrently received the same medication and

exercise regimens described above. Results were generally positive. Firstly, patients who engaged in exercise showed improvements in aerobic capability, with an 11% increase in the exercise
group and a 9% increase in the combination group. Secondly,
depressive symptoms improved equally across all three groups.
Improvements on the HAM-D scores did not differ across
groups, and neither did the scores based on DSM-IV depression criteria. “…The percentage of patients who were no longer classified as clinically depressed at the end of the 4-month
treatment period did not differ across treatment groups.” The
only difference found that they patients benefited more rapidly
in the combination group than did the patients in the exercise
or medication groups alone. This study demonstrated that exercise treatment as an intervention for depression is equally as
effective as medication treatment (Blumenthal, et al. 1999).
Numerous other studies, all of which sought to prove the efficacy
of exercise have tested people who suffer from depression across
the spectrum. One set of studies has shown that participants, ranging from young to elderly, who engage in daily exercise regimens
are far less likely to develop MDD. Subsequent investigation further
demonstrated that daily exercise improves depressive symptoms,
even in people who have not been diagnosed with MDD. Exercise
studies performed with healthy adults with no depressive symptoms also found positive results. These adults reported improved
cognitive function, elevated mood and a general sense of well-being.
One study tested how well exercise treated “moderate-to-severe”
depression, concluding that the depression was highly improved.
Another treated MDD patients with a combination of antidepressant medication and exercise regimens. A control group received
medication and “health education” lessons. The medication/exercise group responded significantly better than the control group.
Yet another tested a group of adults suffering from MDD, exercising with varying intensities of exercise. They found here that the
most intense exercise group improved the most. A significant edge
that exercise has over medication is that the effects of exercise may
extend past the actual regimen, with the positive feelings enduring
(in one study) up to almost two years past the experiment (Ernst,
et al. 2006). This is in sharp contrast to antidepressant medication,
of which the healing abilities curtail immediately with the end of
dosage.This is why people on medication require concurrent therapy so that they can manage their life even after their medication
dosage is over. On the other hand, exercise is found to be even
superior to therapy itself in many instances, with various “young
and middle-aged adults” positing that aerobic exercise helped their
depressive symptoms more than therapies like psychotherapy, CBT
and occupational therapy (Blumenthal, et al. 1999).Aerobic exercise
performed by patients with depression and anxiety may improve
cognitive function. (Heijnen, et al. 2016) Patients who scored poorly
on various task functions, such as Stroop and Flanker Tasks, scored
significantly higher following 30 minutes of aerobic exercise (Ernst,
et al. 2006).All of these studies have consistently found lower MDD
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and anxiety levels in response to exercise training, in addition to
higher psychosocial functioning, increased positive affect and elevated mood (Blumenthal, et al. 1999).
The obvious question that troubles scientists and mental
health specialists is why exercise has such a potent effect on the
human psyche. While the physical action of aerobic exercise is
known to cause weight loss and increased fitness due to burning
of calories and fat and muscle toning, the reason behind the
mental effects are not as simple to extrapolate. Exploring the
neuroendocrine response that takes place in response to aerobic exercise may help to ascertain the underlying cause.
Exercise that activates the heart rate from its resting point
and raises the maximum capacity of oxygen intake (VO2max) at
least 60% can be classified as a physical stressor. In response to
such a stressor, the hypothalamus secretes “corticotrophin-releasing hormone, which travels…to the anterior pituitary to
induce adrenocorticotropic hormone (ACTH) release” into the
general circulation. Arrival of this hormone at the adrenal cortex stimulates cortisol release into the bloodstream. Cortisol
acts as an inhibitor and, through the use of medial prefrontal
cortex (mPFC) receptors, inhibits “overexcitability of the amygdala” that naturally occurs when a stressor arrives in the bloodstream (Heijnen, et al. 2016). This stress response is known as
the Hypothalamic-Pituitary-Adrenal (HPA) Axis, so named for
the journey of hormones from the hypothalamus, through the
anterior pituitary and into the adrenal cortex, causing relaxation from the body’s increased stress levels (Blumenthal, et al.
1999).The elevated levels of cortisol can last up to 2 hours after
the actual exercise action, and the amount of cortisol released
is proportional to the amount of exercise. Equally important
in the stress response is the inactivation of cortisol back into
cortisone. This homeostatic cycle ensures that frequent exercisers do not suffer from extreme cortisol levels that can lead
to “hypertension, hyperglycemia, major depressive episode and
anorexia nervosa” (Heijnen, et al. 2016).Thus, ACTH is a regulatory mechanism that acts as the body’s natural stress response.
This allows one to comfortably exercise without experiencing
the extremely stressful symptoms that characterize psychological stress, such as depression, anxiety, fear, etc. (Angelopoulos,
2001). However, while this neuroendocrine response accounts
for the control of increased psychological stressors while exercising, it could hardly account for the flood of “euphoria, anxiolysis (reduction of anxiety), sedation, and analgesia (relief from
physical pain)” that characterize what we call Runner’s High
(Reynolds, 2015).
Runner’s high is the reason that America has its plethora of
addicted runners clocking miles in their sneakers every day.
Every athlete can describe the “…happiness, elation…inner harmony, boundless energy, and…reduction in pain sensation” that
ensues following prolonged aerobic activity (Dietrich, 2004).
This so-described high is experienced frequently by endurance
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athletes, but really by anyone who exercises profusely for an
extended amount of time. Scientists have struggled for decades
with the reason behind runner’s high and many hypotheses have
been debuted and disproven over time. For years the Endorphin
Hypothesis was the most popular by scientists and the overall
population, gaining strength through hearsay and seemingly impenetrable evidence.
Endorphins are the body’s naturally occurring opiates. When
a person exercises, these chemicals are released in the brain,
seeming to improve the athlete’s mood and promote endurance.
While exercise is known to be a healthful practice to engage in
for one’s physical health, it can cause degrees of discomfort or
even pain. Therefore, it would make sense that in response to
exercise, endogenous opiates with antinociceptive properties
similar to morphine would be released (Reynolds, 2015). Any
kind of intense endurance exercise can induce endorphin release, and it seems that the greater the exercise, more mood-altering endorphins are proportionately released (Kolata, 2008).
Endorphins are “cleaved from the preprohormone pro-opiomelanocortin (POMC)…a protein found in the pituitary gland and
the brain” (Ernst, et al. 2006). The C-terminus of the POMC
protein in turn gives rise to hormones such as opiate peptides.
In one experiment, researchers used PET (positron emission
tomography) scans to compare endorphin levels in the brains
of athletes. Ten athletes did a two-hour run and were tested
for opiate levels before and after the run. Additionally, the runners took a psychological test pre and post-run, intended to
measure their moods before, and in response to, the flood of
endorphins. The researchers did find increased levels of endorphins attaching themselves to the limbic and prefrontal areas of
the brain, zones typically associated with emotion. The athletes
also reported higher mood and euphoria in a seemingly direct
relation to higher endorphin levels in the brain (Kolata, 2008,
Heijnen, et al. 2016). Technically, all this study proved was that
there is indeed a flood of endorphins in the brain in response to
exercise. While there seems to also be a correlation between
the elevated opiate levels and mood, the proof was not – yet
– impenetrable.
A study performed at the Iranian Academic Center for
Education, Culture and Research (ACECER) attempted to ascertain how endorphin levels are affected due to exercise. The
researchers included subjects with fibromyalgia (FM) as well as
healthy patients.The study was based on the assumption that exercise increases release of endogenous β-endorphins, and that
β-endorphins lessen pain perception. Exercise has previously
been used as a treatment for diseases such as FM, with a strong
role in nociception and elevated pain threshold. Specifically in
FM cases, however, the “analgesic effect” or lessening of pain
perception seemed significantly dulled. According to the results
of the study, this would seem to be due to the fact that FM patients produce less β-endorphins as they exercise and therefore
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are less capable of blocking pain. All of the subjects first rested
in a supine position in order to attain their basal heart rate, a
range of 60 to 100 beats per minute. Blood from the anti-cubital
vein was drawn at baseline and at the end of the exercise test
in order to compare β-endorphins levels. The exercise test was
a treadmill routine that continued as long as the subject was
able, until the onset of “fatigue, pain, or physical exhaustion”.
Every three minutes the incline of the treadmill as well as the
speed increased according to specific intervals. As soon as 70%
of the patients HRMax (maximum heart rate) was achieved, the
subject was told to continue for 15 more minutes only, and
their level of exercise intensity was recorded. The post exercise
blood was drawn directly afterwards, when the heart rate was
still at its maximum. The results were rather interesting. The
mean exercise times for the FM and healthy groups revealed
that it took a much shorter time for the FM subjects to achieve
HRMax than the healthy group. The majority of subjects who
were able to reach their HRMax at later stages of exercise were
from the healthy group. Ninety three percent of the healthy
group, as opposed to the mere 30% of FM subjects, reached
HRMax during stage four of exercise. This indicated that FM
patients were unable to exercise to the same extent that the
healthy participants were. While the blood samples indicated
that both groups had amounts of β-endorphins, the FM subjects
has significantly lower levels in both their baseline blood and
in the post-exercise blood. This means that while both groups
experienced a rise in β-endorphins due to the exercise, the FM
patients were unable to produce the same influx of β-endorphins as the healthy group.These blunted levels of β-endorphins
may explain why FM patients are more immune to the analgesic
effects of exercise that usually take over post-exercise. Usually,
aerobic exercise stimulates elevated β-endorphins levels which
in turn seem to stimulate decreased nociception, elevated
mood and psychological stability. However, due to “failure of
normal elevation of [endogenous] β-endorphins,” FM patients
seem less able to produce the same analgesic effects. Therefore,
they might be more prone to develop chronic allodynia (pain
from a non-painful stimulation of the skin) and heightened nociception with the absence of normal β-endorphins levels (Bidari,
et al. 2016).
Scientists have explored how endorphin levels rise in response to exercise. A study sought to verify the elevated levels
of endorphins, with and without naloxone (opiate antagonist).
It has already been proven than exercise with an intensity of
75% of VO2max and 80% of HR (heart rate) causes an elevated
release of beta endorphins into circulation. However, this study
examined whether longer lengths of activity cause even further
increased endorphin levels, and how long one must exercise to
stimulate endorphin release. The study included “nine healthy,
fit males.” In this double-blind experiment, some subjects were
injected with naloxone, and some with a mere placebo. They

all took a graded exercise test (GXT) to assess their physical
capabilities and then performed exercise on treadmills, running
until they were too exhausted to go on. Phlebotomy techniques
were used to draw blood and measure beta endorphin levels.
Levels of VO2max, HR (heart rate) and hematocrit (ratio of
RBC volume in blood) were measured during 10 min, 20 min
and 30 min intervals for both trials. No changes in Hct levels
were found between trials.
β-endorphin concentration across the trials were recorded
and trials showed significant differences. Before exercise, β-endorphins levels were at roughly 40 ml; across 10, 20 and 30-minute intervals, influxes of 80 to 90 ml of β-endorphins were recorded. Of note is that after the initial rise in β-endorphins, the
volumes leveled off and stopped rising across time during exercise - it stayed constant. β-endorphin levels were significantly
higher under naloxone administration.To summarize the results
of the study, a significantly large increase in β-endorphin were
found during and throughout exercise as compared to resting
levels. They also found that the men injected with Naloxone experienced even higher levels of β-endorphins. Additionally, tests
with low to moderate levels of exercise showed no changes
at all in β-endorphin levels. Therefore, this suggests that it is
only intense aerobic exercise that induces significant increases
in β-endorphins. This elevation occurs rapidly from the onset
of exercise and remains level through the duration. This test
found much higher β-endorphin levels in the naloxone-injected
participants as compared to the placebo participants. However,
other experiments did not find much of a difference between
naloxone test and placebo test. This is an obvious disparity that
may be due to “differences in the exercise protocol, method of
administration of the antagonist, and in the stereo-specificity of
the antagonist used in the respective experimental protocols”
(Angelopoulos, 2001).
Now the question stands, what is it that causes this drastic β-endorphins rise during exercise? The researchers suggest
that Naloxone attaches to the opioid receptor, blocking any
other opiates and signaling the pituitary gland to release more
β-endorphins. These β-endorphins do glucoregulation during
exercise, “augmenting glucagon levels and attenuating insulin
release.” Glucagon keeps blood glucose at high enough levels
to allow the body to function normally (Glucagon, Diabetes.
Co). This is a positive feedback loop – more β-endorphin is released, it does more glucoregulation, and so more β-endorphin
is released. This may be why endorphin levels were higher with
Naloxone injections.
ACTH also increases under stressful condition, just like β-endorphins. ACTH is also secreted by the pituitary and regulates
cortisol in the bloodstream. Just like the endorphins in this
study, ACTH levels rise with an injection of Naloxone. Thus, it
seems that both β-endorphins and ACTH are regulatory mechanisms, acting to ensure the body’s homeostasis despite outside
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stressors. However, ACTH regulates the psychological stress
response and endorphins normalize the physical response.
This study demonstrated how and why β-endorphins levels
were significantly elevated over the course of aerobic activity
(Angelopoulos, 2001).
It is clear that aerobic exercise indeed causes an influx of
β-endorphins to be released into blood circulation.The next step
would be to secure as fact that it is indeed the flood of endorphin
opiates that lowers depressive symptoms and induces a euphoric
affect. The following study attempted to ascertain the possible
link between aerobic exercise and the subjects’ emotional state.
The study involved middle aged subjects engaging in physical activity. First off, the subjects’ emotional states were evaluated using
FaceReader. FaceReader is a facial analysis software that assesses
emotional state based on 6 primary emotions - happy, sad, angry,
disgusted, scared, and surprised. The subjects were also interviewed personally to assess how they were feeling just then.After
the facial analysis the researchers drew blood from the median
cubital vein of each subject to have a baseline sample of blood
plasma levels. The physical activity was measured using a veloergometer load test.A veloergometer is similar to an elliptical exercise bike, however it is equipped with specialized hardware capable of measuring physical prowess.This exercise regimen is called
a load test, and it commenced for a half hour, with increasing
load every three minutes. After the load test, the pre-test procedures – FaceReader, interview and phlebotomy – were repeated
and analyzed. The pre and post blood measures were tested for
plasma beta endorphin levels to see if there was an increase in
endorphins in response to the exercise. If an increase was accompanied by a similar increase in mood, this would provide evidence
that it is endorphins that cause the elevated mood associated
with physical activity.The results showed an endorphin increase in
only half of the subjects. However, in regard to positive affect, the
data found a general increase across the subjects. A 20% increase
in happiness was found and all except one showed a decrease in
negative emotions. (One subject showed an increase in disgust
due to unpleasant lab conditions) (Kundzina, et al. 2014). These
findings definitively supported the hypothesis that extended aerobic exercise of at least 60% VO2 intensity is directly linked to
increased positive affect and decreased depressive symptoms. It
is of significance to note, however, that only half of the subjects
showed a marked increase in circulating beta endorphin levels.
Here we introduce a hypothesis that closely allies with the subject at hand. This is the Neurogenesis Hypothesis, which states
that “a decrease in the synthesis of new neurons in the adult hippocampus might be linked to major depressive disorder (MDD).”
Anti-depressant medications such as SSRIs have been used for
years as treatment for MDD. Anti-depressants act to stimulate
synthesis of new neurons in the adult brain. Eventually, a link was
drawn between the anti-depressants and neurogenesis, since the
time it takes for medication to have an effect is the same span of
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time it takes for the newly synthesized neurons to gain functionality. Returning to our exercise hypothesis, an experiment with
lab rats found a 2 to 3-fold increase in neurogenesis in rats who
had “regular access to a running wheel when they are compared
with control animals.” This discovery naturally led to the awareness that exercise assuages depressive symptoms by inducing
increased neurogenesis, the “growth of new neurons in the adult
[mammalian] brain.” While it was once thought that neurogenesis
is limited to the developmental stages of growth, it is now known
that certain areas of the adult mammalian brain retain active progenitor cells that are constantly synthesizing new neurons and glial
cells.There are two major sites of adult neurogenesis, the dentate
gyrus of the hippocampus and the subventricular zones adjacent
to the lateral ventricles. Based on experiments performed with
lab mice and rats, roughly 9,000 new neurons are synthesized
daily in the dentate gyrus alone. Research indicates that these
numbers are reflective of human neurogenesis as well (Ernst, et
al. 2006). One site of adult neurogenesis is the subventricular
zone (SVZ) that is adjacent to the lateral ventricles of the brain.
“Numerous proliferative precursor cells” line the walls of the
ventricles that are composed of ependymal cells. The precursor
cells are contained in this zone and eventually mature into new
neurons and glial cells.The second site is the dentate gyrus (DG),
located on the hippocampus in the brain. The hippocampus, a
“bilateral limbic structure that plays a role in…learning and memory....” has two distinct areas – the Cornu Ammonis (CA) and the
dentate gyrus. The CA has three subfields filled with pyramidal
cells, multi polar neurons that act as primary excitation neurons
in the brain. The dentate gyrus is connected to the CA and is
“composed of small, round granule cells” that form a C shaped
area. It is underneath these granule cells that active progenitor
cells are housed and give rise to new neurons and glia, giving the
area its name – the subgranular zone (SGZ) of the dentate gyrus.
The two zones are closely adjacent to each other but develop
differently. Active progenitor cells in the dentate gyrus give rise
to daughter cells that migrate into the granule layer above.There,
they develop and send out axons into the Cornu Ammonis region
3 (CA3). Over the course of four to five weeks, these daughter
cells mature and act like fully grown granule cells. The daughter
cells in the subventricular zone give rise to daughter cells that
migrate into the olfactory bulbs to act as local interneurons.Thus,
there is adult neurogenesis occurring daily at a rapid rate in the
healthy mammalian brain. The neurogenesis theory states that if
this complex process should somehow be impaired and fewer
neurons would be created, the result would be the expression
of depressive symptoms. The introduction of anti-depressant
medications would promote neurogenesis and get the brain back
on track. The plot thickens with the discovery that exercise too,
promotes neurogenesis in the hippocampus of the brain. This
strongly links exercise as a reliable therapeutic intervention for
treatment of MDD (Ernst, et al. 2006).
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Several research experiments have sought to augment the
proof with concrete data. Firstly, MRI (magnetic resonance imaging) data have shown that hippocampal volume is severely
compromised in the brains of depressed patients. This would
give strength to the idea that it is reduced neurogenesis in the
dentate gyrus that gives rise to depressive symptoms. Other
studies showed that the corticosteroids released from the adrenal gland as part of the natural stress response (HPA Axis)
negatively impact neurogenesis in the hippocampus, thus causing the “decreased hippocampal volume associated with MDD.”
The stress response is thus amplified, sustaining a vicious cycle
of continuous depression and stress response. It’s important to
note that the decreased size of the hippocampus is not due to
the degeneration of pre-existing neurons. Therefore, it would
follow that fewer neurons are being created in the first place.
Comparatively, researchers found increased hippocampal volume in direct relation to aerobic exercise. Lab rats that engaged
in aerobic exercise consistently displayed large increases in hippocampal volume due to subsequent supplementary neurogenesis. As compared to control mice and rats with no access to a
running wheel, active mice displayed double the number of new
neurons in the subgranular zone of the dentate gyrus of the
hippocampus. Furthermore, it has been ascertained that treatments for MDD, such as SSRIs (selective serotonin reuptake
inhibitors) or electroconvulsive shock therapy, also cause an increase in neurogenesis. This expresses a direct relationship between neurogenesis and lessening depressive symptoms. A third
proof involves the timing. Newly generated neurons typically
require four to five weeks to become fully functioning neurons.
This is a “latency similar to the onset of therapeutic benefit
for most…antidepressant medication[s].” This information also
supports the idea that proper neurogenesis is integral to reducing depressive symptoms. Research has even shown that in
certain cases, aerobic exercise can foster the same therapeutic
effects as cognitive therapy (Ernst, et al. 2006).
Further research implicates BDNF (Brain-Derived
Neurotrophin Factor) in exercise-induced neurogenesis. BDNF
promotes “neuronal survival and regeneration” in the adult
brain. Aerobic exercise causes elevated levels of BDNF to be
produced specifically in the CNS. This specificity indicated that
BDNF plays a particularly central role, namely in the brain. One
study found that exercise in mice led to increases in BDNF.They
also noted that in a case with depressed lab animals, exercise led
to an increase in both BDNF levels and hippocampal neurogenesis. On the other hand, it is known that it is neurogenesis that
causes the anti-depressant effects of exercise; therefore, it was
concluded that elevated levels of BDNF contribute to increased
neurogenesis, thus playing an indirect role in lowering the depressive symptoms. BDNF stimulates cell proliferation specifically in the subgranular zone of the dentate gyrus, and also
supports long-term survival of these new neurons. A positive

cycle can thus be recognized: exercise increases BDNF, BDNF
enhances neurogenesis and neuronal survival, causing increased
positive affect, probably leading to further exercise to prolong
the effect (Ernst, et al. 2006).
The obvious question is: why does exercise stimulate neurogenesis; what endogenous substance causes the brain to up the
ante on neurogenesis when the body is engaged in aerobic activity? This returns us to the endorphin hypothesis. The thought
was that endorphins are what stimulate increased neurogenesis,
in turn causing a decrease in MDD. Studies have found that not
only do infusions of opiate peptides seem to cause an increase
in neurogenesis in the dentate gyrus, but also that “opiate receptor antagonists” seem to cause a decrease in adult neurogenesis. Therefore, endorphins may have a role in the survival
and/or formation of new neurons and glia (Ernst, et al. 2006).
The Endorphin Hypothesis seemed sound, and was sustained
for decades in the medical arena and among lay athletes at
large. However, significant holes in the hypothesis were sprung
that threatened the authenticity of its claims. Among other
problems, the most substantial issue was that of the Blood
Brain Barrier (BBB). Blood Brain Barrier describes the precise “microvasculature of the central nervous system.” It is a
semipermeable border separating the blood circulation from
the brain and ECF (extracellular fluid of the CNS). This system of tightly packed endothelial cells (in the capillary wall),
astrocytes (covering the capillaries) and pericytes (embedded
in the basement membrane of the capillaries) is able to control
the movement of substances to and from the brain and blood
circulation. Substances such as “molecules, ions, and cells” are
screened heavily by the BBB to ensure that no harmful microbes or other destructive substances reach the brain. This
system ensures proper neuronal function and protection of the
brain and spinal cord against “toxins, pathogens, inflammation,
injury, and disease” (Daneman, R, et al. 2015). Since the cells of
the BBB are so tightly packed, certain molecules that are too
large are unable to pass through to gain access to the Central
Nervous System. An example of such large molecules are beta
endorphins. They are too bulky to pass through the BBB and
therefore cannot be the cause any changes to occur within the
brain. So, while endorphins are indeed released during exercise and may staunch peripheral muscle pain that results from
exercise, they cannot be the source of any Runners’ High or
diminished depressive affect (Reynolds, 2015, Fuss, et al. 2015,
Dietrich, 2004). Other “methodological confounds” inherent in
the endorphin hypothesis are as follows:
1. Firstly, the possibility of cross reactivity is very strong. Cross
reactivity occurs when two antigens are very similar in
their amino acid makeup and therefore an antibody raised
against one antigen might also bear an affinity for the similar antigen. The antibody is “programmed” to find the first
antigen but it also recognizes the second. Beta endorphins
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bear almost identical amino acid sequences with adrenocorticotropic hormone (ACTH) and other pro-opiomelanocortins.Therefore, any detecting antibody would possibly
cross-react, making it difficult to detect which is which.
(Proteintech, 2018) This is a serious confound for scientific experiments involving the authentication of the beta
endorphin hypothesis and possibly invalidates much of the
proof presented from these experiments. The fact that endorphins have similar structure specifically to ACTH is a
further confound, since ACTH is also known to increase
with endurance exercise.
2. Furthermore, when beta endorphins bind to a µ opioid receptor, it activates the “endogenous opioid system” that further
activates the “analgesic and euphoric properties” inherent in
the opiate system. It is also known, however, that symptoms
such as “severe respiratory depression, pinpoint pupils, and
inhibition of gastrointestinal motility” are all characteristic of
endogenous opioid activation (Dietrich, 2004). If it were beta
endorphins that were activating the opioid system, these
symptoms would also be present in runners and endurance
athletes. Since they are not, we are forced to reevaluate what
it is that truly causes Runners’ High.

Endocannabinoids
Researchers and scientists have now turned their attention
to endogenous endocannabinoids as the true source of analgesia, sedation, anxiolysis and reduced depression found in
endurance exercisers (Dietrich, 2004, Heijnen, et al. 2016).
More recent studies are focusing on endocannabinoids and
what is it about them that makes exercise “mildly intoxicating” (Reynolds, 2015). Endogenous endocannabinoids are the
body’s natural chemicals that improve mood and reduce nociception. They are endogenous lipids that “engage cannabinoid
receptors, producing analgesic and euphoric effects just like
those of exogenous cannabinoids, namely marijuana (or cannabis - Δ-9-THC ((–)-trans-Δ9-tetrahydrocannabinol; THC) (Lu,
et al. 2016, Reynolds, 2015). While we now know that opiate
endorphins mediate analgesia on a peripheral level, we have
seen that there are still analgesic effects that occur irrespective
of a working opioid system. This supports the evidence that
cannabinoid induced analgesia also takes place at a central level
(Dietrich, 2004). Endocannabinoids are what tell the hypothalamus to induce the release of endorphins. Therefore, any analgesic effects that endorphins do have are actually mediated
by endocannabinoids (Heijnen, et al. 2016). Unlike endorphins,
endocannabinoids are small enough to cross the Blood Brain
Barrier and bind to brain receptors, thus enabling them to induce peripheral as well as central effects (Fuss, et al. 2015). An
interesting feature of cannabinoid function is that way they are
produced. Classic neurotransmitters are created ahead of time
and stored in their respective synaptic vesicles for whenever
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they might be needed. Cannabinoids, on the other hand, are created and released almost immediately on demand. When called
upon, for example, by G protein coupled receptors or during
depolarization, endocannabinoids will be “liberated in one or
two rapid enzymatic steps and released into the extracellular
space” to produce a rapid effect on the system (Lu, et al. 2016).
There are two types of identified endocannabinoids, CB1 and
CB2. CB1 can be found in the CNS, “densely concentrated” in
the cerebral cortex, hippocampus, basal ganglia; amygdala, hypothalamus and cerebellum (Dietrich, 2004). Most CB1 receptors
are found on axon terminals and pre-terminal axon segments,
not on the active zones (Lu, et al. 2016). This further elevated endocannabinoids over endorphins, for while endorphins
cannot even cross over in to the brain, endocannabinoids are
located in the places one would assume pain relievers and analgesics would be found. The hippocampus is a site for memory,
as well as neurogenesis which reduces depression; the amygdala
regulates the fear response; the hypothalamus is the “master
gland” of the brain and orchestrates all incoming and outgoing
activity. The cerebral cortex is a massive conglomeration with
numerous functions that would be affected by endocannabinoids.The frontal lobe of the cortex cares for “higher executive
functions” such as “emotional regulation, planning [and] reasoning…” The parietal lobe is responsible for sensory integration
such as touch, temperature and pain perception. Thus, is makes
sense that these areas would abound with CB1 receptors. CB2
receptors are mainly located in the PNS, expressing themselves
on immune cells, microglia and vascular elements to protect the
CNS. (Lu, et al. 2016) There are also cb1 receptors on peripheral nerve terminals. For example, “pain sensing [small diameter] C fibers, large diameter Aß and Aδ fibers… [and] dorsal
root ganglia” (Dietrich, 2004). Therefore, we see that ECBs are
synthesized both centrally and peripherally, unlike endorphins
which hare only synthesized in the Peripheral Nervous System.
The possibility of a third cB receptor is currently being investigated and may turn out to account for some of the Runners’
High effects.
Chief ligands of CB1 and CB2 receptors are anandamide
(arachidonoyl ethanolamine) and 2-arachidonoyl glycerol (2AG) (Lu, et al. 2016). They are derived from fatty acid derivatives. Anandamide is known to bind with cb1 receptors over
cb2 receptors, indicating higher central activity over peripheral
activity (Dietrich, 2004). Anandamide (AEA) is a “highly lipophilic” fatty chemical and therefore can easily cross in to the brain
proper (Heijnen, et al. 2016). This would implicate anandamide in
activating analgesic effects in the brain (Dietrich, 2004). AEA increased gradually when cortisol is released during the HPA Axis,
demonstrating a role in regulation of stress and amygdalar over
excitability (Heijnen, et al. 2016). Rats showed an increase in hippocampal anandamide after running on a wheel for an extended
period of time, indicating that anandamide plays a role in exercise
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and homeostatic regulation (Fuss, et al. 2015). Additionally, anandamide acts as a vasodilator and produces hypotension, facilitating blood flow during exercise (Dietrich, 2004).
Anandamide (AEA) also engenders elevated levels of BDNF
(Brain Derived Neurotrophic Factor) during exercise and return
to baseline levels post-exercise. As mentioned above, BDNF is
part of the neurotrophin family and plays a strong role in exercise-induced neurogenesis. In addition to promoting positive
affect due to neurogenesis, BDNF also “exerts beneficial effects
on cognition through its ability to enhance neurogenesis, synaptic plasticity and long-term potentiation, the basis of learning.”
Therefore, enhanced release of AEA due to exercise stimulates
BDNF to stimulate heightened cognition and learning. Indeed,
psychological stress and mood disorders have been found to reduce BDNF levels in the brains of rats and mice. Physical stress,
or aerobic exercise, does just the opposite. A study among an
elderly population showed that “moderate intensity walking”
over a year served to intensify BDNF levels, further causing task
switching functioning to remain constant. The control group of
sedentary elderly showed a diametric decline in BDNF and
in task switching as well (Heijnen, et al. 2016). Other studies
have shown that aerobic activity “ranging from 20 to 90 min
of 40–75% of maximal power output or 40–60% of VO2max
or 75% of maximal heart rate” causes noticeable increases in
BDNF levels (Heijnen, et al. 2016). Thus endocannabinoids play
a role in cognition and mood as well.
Scientists noted that there were elevated levels of both endorphins and endocannabinoids in the plasma of mice, post run
(Reynolds, 2015). In one experiment, the cB receptors in mice
were blocked, noticeably inhibiting the Runners’ High that is
usually induced post run. The mice were anxious and sensitive
to pain perception. Blocking the endorphin receptors had no
effect and the mice experienced the calming and antinociceptive
effects of runners’ high as usual (Fuss et al., 2015, Reynolds,
2015). A similar study also involved lab mice running in a wheel.
First off, increased running directly increased levels of endocannabinoids, effectively inducing a reduction in anxiety and pain.
Furthermore, ablation of the mice’s cb1 receptors completely
inhibited the runners’ high effect, eliminating anxiolysis. When
the mice were injected with blockers of their cB receptors,
the analgesic effects were further inhibited (Fuss, et al. 2015).
Yet another study with mice divided the mice into running and
non-running groups. The running mice were at ease to spend
more time in bright light areas, something anxious mice don’t
do. This indicated that the running induced sedation. The mice
were also tested for pain perception with a hot plate test. The
runners did not jump in pain or lick their paws as much as
normal, indicating that running induced antinociception, endowing the mice with heightened “thermal pain sensitivity.” All of
these studies found that reductions in anxiety and elevated sedation in mice are due to increased CB1 receptors in forebrain

GABAergic neurons, while antinociception was caused by cb1
and cb2 receptors in the PNS (Fuss, et al. 2015). This antinociceptive effect can even rival that of morphine (Dietrich, 2004).
Another study engaged healthy male athletes running at
“varying degrees of intensity” over a period of four days. Each
running session induced a 70-80% raise in basal heart rate, and
was performed at 50-90% of maximal intensity capacity. A sharp
increase in cB1 receptors was found in the “frontal cortex,
amygdala, hippocampus, and…hypothalamus” all known to be
essential areas that regulate affective homeostasis (Heijnen, et
al. 2016). A similar study involved male college athletes exercising on treadmills or stationary bikes at 70-80% maximal heart
rate. After about an hour, drastically raised levels of anandamide
were measured in their blood circulation (Dietrich, 2004).
Another way that endocannabinoids modulate nociception
is by affecting the Periaqueductal Gray system (PAG). The PAG
serves an important role in modulating ascending pain transmission, fielding “afferents from nociceptive neurons in the spinal
cord [and sending] projections to thalamic nuclei that process
nociception.” In regard to descending pain inhibition, the PAG
inhibits neurons in the dorsal horn of the spinal cord.The major
functions of the midbrain periaqueductal gray (PAG) include
suppressing pain, fear and anxiety, and promoting analgesia and
cardiovascular control” (Bebehani, 1995). “Electrical stimulation
of [both] the dorsal and lateral periaqueductal gray system”
causes not only bindings to cb1 receptors but a subsequent release of anandamide into circulation. Additionally, an experiment
revealed that “subcutaneous injection of the chemical irritant
formalin” caused a direct infusion of the ligand anandamide into
the periaqueductal gray. This implicates anandamide as a nociceptive agent for central chemogenic pain (Dietrich, 2004).
Upon observation, it can be noted that runners’ high is only
found in response to endurance exercise, as opposed to exercise in spurts. Sports such as “sprinting…weightlifting…track,
soccer, football, tennis [and] basketball” doubtfully engage the
endocannabinoid system since they do not involve long term
exertion (Dietrich, 2004). Running, dancing or biking are examples of activities that would engage the ECB system and
induce a runners’ high. As mentioned earlier, endorphins play
a role in moderating only peripheral chemogenic pain in the
muscles. In addition to the central effects of anandamide, we
find that cannabinoids also act similarly to inhibit edema and
muscle inflammation that might occur during intense exercise.
This moderation is important for endurance athletes because
muscle pain is a cause and effect of lactic acidosis, which in turn
introduces symptoms like muscle ache, nausea and stomach
pain (Dietrich, 2004).
Endogenous cannabinoids and exogenous cannabinoids (marijuana) act in similar fashions. “The psychoactive constituent of
marijuana, Δ-(9)-tetrahydrocannabinol (THC), exhibits high affinity for the CB1 receptor, which is densely expressed in brain
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regions implicated in the control of emotion and cognition.”
Therefore, just like marijuana, ECBs can induce sedation, analgesia, reduced anxiety, euphoria and even impaired spatial learning
(Dietrich, 2004). This essentially means that prolonged exercise
produces the same effects as marijuana.
This leads into the addictive quality of endurance exercise.
The endocannabinoid system is closely linked with the dopaminergic reward system of the brain. Dopamine is the brain’s
pleasure hormone, and dopamine receptors D1 and D2 are
modulated by endocannabinoids. The two main ECB ligands
anandamide and 2-arachidonoylglycerol (2-AG) proliferate in
dopaminergic pathways as a “retrograde feedback system” for
GABA nerve terminals. There, they modulate dopamine transmission (Bloomfield, et al. 2016). Additionally, cBs affect dopamine activity by increasing firing rates in the medial forebrain
bundle, ventral tegmentum and substantia nigra. In the same
vein, withdrawing the cB presence would induce withdrawal
symptoms similar to that characteristic of marijuana withdrawal.
This is due to reduced firing of the pleasure hormone dopamine.Therefore, endogenous as well as exogenous cannabinoids
(CB1) are what cause the influx of dopamine release into circulation, thus causing a feel-good high or a “Runners’ High.” Just
like exogenous ECB cause drug addiction, so too endogenous
ECBs engender an addiction to that which brings on the dopaminergic feelings, namely aerobic exercise.This explains exercise
addiction; exercise causes elevated levels of ECBs, ECBs in turn
cause increased firing of dopamine, inducing an addictive “high.”
Indeed, it has been found that even just blocking dopamine
receptors inhibits Runners’ High. Athletes who are forced to
refrain from their routine endurance exercise (for example, in
the case of an injury) report withdrawal symptoms not unlike
those of drug withdrawal (Dietrich, 2004).

Conclusion
The analgesic, euphoric and anti-depressant effects that take
hold in response to aerobic exercise have been a major source
of contention among the medical, scientific and lay community
for decades. The endorphin hypothesis certainly took center
stage for quite a time as the source behind what the vernacular
aptly termed “Runners’ High.” However, compelling evidence,
experimental proofs and biological veracities have enabled scientists to ascertain that endogenous endocannabinoids are the
underlying cause of the many positive effects of aerobic activity.
Included in these positive effects are: elevated ACTH to regulate
the stress response, heightened BDNF production to promote
neurogenesis and neural survival, analgesia, anxiolysis, decreased
anxiety and depression, euphoria, enhanced cognition, and numerous others. Endorphins do not cause Runners’ High; however, they do engender other positive effects during exercise.
Exercise has been seen to induce Runners’ High in all ages and
stages, be it depressed or emotionally healthy, young or elderly,
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and male or female. With this knowledge, the proof holds true
that enhanced release of endogenous endocannabinoids due
to aerobic activity reliably and consistently induces a Runners’
High, and thus decreases the depressive symptoms inherent in
Major Depressive Disorder.

Bibliography
Angelopoulos,T. J. (2001). Beta-endorphin immunoreactivity
during high-intensity exercise with and without opiate blockade.
European Journal of Applied Physiology, 86(1), 92-6. doi:http://
dx.doi.org/10.1007/s004210100501
Behbehani, MM, “Functional characteristics of the midbrain periaqueductal gray”, Department of Molecular and Cellular Physiology,
University of Cincinnati College of Medicine, OH 45267-0576,
USA, August 1995, retrieved from https://www.ncbi.nlm.nih.gov/
pubmed/8545545
Bidari, A., Ghavidel-Parsa, B., Rajabi, S., Sanaei, O., & Toutounchi, M.
(2016).The acute effect of maximal exercise on plasma beta-endorphin levels in fibromyalgia patients.The Korean journal of pain,
29(4), 249–254. doi:10.3344/kjp.2016.29.4.249
Bloomfield, M. A., Ashok, A. H.,Volkow, N. D., & Howes, O. D.
(2016).The effects of Δ9- tetrahydrocannabinol on the dopamine
system. Nature, 539(7629), 369–377. doi:10.1038/nature20153
Blumenthal, James A. PhD; Michael A. Babyak, PhD; Kathleen A.
Moore, PhD; et alW. Edward Craighead, PhD; Steve Herman, PhD;
Parinda Khatri, PhD; Robert Waugh, MD; Melissa A. Napolitano,
MA; Leslie M. Forman, MD; Mark Appelbaum, PhD; P. Murali
Doraiswamy, MD; K. Ranga Krishnan, MD, Effects of Exercise
Training on Older Patients With Major Depression, October 25,
1999, Arch Intern Med. 1999;159(19):2349-2356. doi:10.1001/
archinte.159.19.2349
https://jamanetwork.com/journals/jamainternalmedicine/
article-abstract/485159
Daneman, R., & Prat, A. ().The blood-brain barrier. Cold Spring
Harbor perspectives in biology, 7(1), a020412. doi:10.1101/cshperspect.a02041
Diabetes.Co.UK,The Global Diabetes Community, retrieved from
https://www.diabetes.co.uk/body/glucagon.html
Dietrich A, McDaniel WF, Endocannabinoids and exercise, British
Journal of Sports Medicine 2004;38:536-541. https://bjsm.bmj.
com/content/38/5/536
https://www.frontiersin.org/articles/10.3389/fpsyg.2015.01890/full
Ernst, C., Olson, A. K., Pinel, J. P. J., Lam, R. W., & Christie, B.
R. (2006). Antidepressant effects of exercise: Evidence for
an adult-neurogenesis hypothesis? Journal of Psychiatry &
Neuroscience: JPN, 31(2), 84-92. Retrieved from https://search.
proquest.com/docview/217297036?accountid=14375
Fuss, Johannes Steinle, Jörg Bindila, Laura Auer, Matthias K.
Kirchherr, Hartmut Lutz, Beat Gass, Peter (2015), A runner’s
high depends on cannabinoid receptors in mice, National
Academy of Sciences, Electronic Journal Article, 10.1073/

Endorphins, Endocannabinoids and Runners’ High

pnas.1514996112, URL http://www.pnas.org/content/
early/2015/09/29/1514996112.abstract
Harvard Health Publishing, Harvard Medical School, March 19,
2019, “What are the real risks of antidepressants?”
Heijnen, Saskia Hommel, Bernhard Kibele, Armin Colzato,
Lorenza S., Neuromodulation of Aerobic Exercise—A Review,
{Frontiers in Psychology},VOLUME={6}, PAGES={1890}, (2016},
Retrieved from https://www.frontiersin.org/article/10.3389/
fpsyg.2015.01890}, (10.3389/fpsyg.2015.01890}, ISSN =
{1664-1078},
Kolata, G. (2008, Apr 01). Science proves runner’s high.
The Ledger Retrieved from https://search.proquest.com/
docview/390396928?accountid=14375
Science Proves Runner’s High
Gina. The; Lakeland, Fla. [Lakeland, Fla]01 Apr 2008.
Kundziņa, I., & Grants, J. (2014). The Relationship between
Beta Endorphins and Emotional State in Physically Active
Individuals Aged 45-55 (A Report on a Pilot Study). Polish
Journal of Sport & Tourism, 21(3), 147–150. Retrieved from
http://search.ebscohost.com/login.aspx?direct=true&db=s3h&AN=99046827&site=ehos t-live
Lu, H. C., & Mackie, K. (2016). An Introduction to the
Endogenous Cannabinoid System. Biological psychiatry, 79(7),
516–525. doi:10.1016/j.biopsych.2015.07.028
Oleson, E. B., & Cheer, J. F. (). A brain on cannabinoids: the role
of dopamine release in reward seeking. Cold Spring Harbor
perspectives in medicine, 2(8), a012229. doi:10.1101/cshperspect.a012229
Proteintech group, How Do I Know if the Antibody Will Cross
React, March 27, 2018, retrieved from https://www.ptglab.com/
news/blog/how-do-i-know-if-the-antibody-will-cross-react/
Queensland Brain Institute, University of Queensland, Australia,
Lobes of the Brain, July 17, 2018, Retrieved from https://qbi.
uq.edu.au/brain/brain-anatomy/lobes-brain
Reynolds, Gretchen, Homing in on the Source of Runner’s
High, October 7, 2015, Retrieved from the NewYorkTimes,
PHYS ED, https://well.blogs.nytimes.com/2015/10/07/
homing- in-on-the-source-of-runners-high/
Sulak, Dustin, Introduction to the Endocannabinoid
System, NORML, Workingot Reform Marijuana
Laws, retrieved from https://norml.org/library/item/
introduction-to-the- endocannabinoid-system

33

